TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31819393
Drug: Oscillatory PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillatory PEP (OPEP) therapy
Study: 24005444
Drug: PEP therapy
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEP therapy
Study: 31819393
Drug: PEP ±
Normalized name: Postexposure prophylaxis (PEP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP ± OM therapy
Study: 22878749
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 1000 mg daily
Study: 22878749
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 1000 mg daily plus erlotinib 150 mg
Study: 20972904
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (group B)
Study: 17097647
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) alone (100 mg/day from day 3 to day 7; n = 56)
Study: 17097647
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) in combination with pure FSH (75 IU on day 3 and day 8; n = 54)
Study: 17097647
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (parous women, n = 18)
Study: 2407957
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (75 mg per day)
Study: 394752
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate 800 microgram daily
Study: 394752
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate 400 microgram daily
Study: 25260444
Drug: Standard inguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inguinal varicocelectomy plus oral L-carnitine therapy (250 mg 3 times a day for 6 months)
Study: 22552034
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone supplementation (80 mg daily for 6 weeks)
Study: 19959293
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment (IV opioids)
Study: 18166126
Drug: Nystatin (nonabsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (nonabsorbed antifungal drug)
Study: 26028965
Drug: Anagrelide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide therapy
Study: 12045085
Drug: Intramuscular droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular droperidol 2.5 mg
Study: 12045085
Drug: Intramuscular dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular dimenhydrinate 50 mg
Study: 9524997
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole vaginal gel (twice daily for 7 days)
Study: 9524997
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (250 mg, three times daily for 7 days)
Study: 9524997
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole and 0.75% metronidazole vaginal gel
Study: 8585295
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate adsorbed vaccine
Study: 8585295
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide adsorbed vaccine
Study: 8305355
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg t.d.s.
Study: 2533896
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg t.d.s.
Study: 773484
Drug: Intraperitoneal noxytiolin
Normalized name: Noxytiolin
DrugBank: Noxytiolin (DB13838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal noxytiolin (Noxiflex) solution
Study: 30949182
Drug: Extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal photopheresis (ECP) therapy
Study: 27119829
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day co-administered with atorvastatin 20 mg
Study: 26030325
Drug: Doubling atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling atorvastatin dose
Study: 24508320
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus treatment as usual
Study: 22395889
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of ocular hypotensive medication
Study: 17343552
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at low, medium, and high doses
Study: 10578595
Drug: Composite Indian
Normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Indian herbal preparation (CIHP)
Study: 8694025
Drug: Lactose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose supplementation (0.6 to 1.0 g.kg‐1.d‐1, divided into three doses) for 10 days
Study: 8694025
Drug: Lactose challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose challenge (0.35 g/kg) after overnight fast
Study: 6318345
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg per day ketoprofen alone
Study: 6318345
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg per day ketoprofen combined with 1,500 mg aspirin
Study: 26384629
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to a recorded CD of music and songs preferred by the child)
Study: 23790566
Drug: D-amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (0, 5, 10, and 20 mg)
Study: 21283923
Drug: Both LF
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both LF and HF treatments
Study: 19135671
Drug: Glimepiride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (4 mg od)
Study: 19135671
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg od)
Study: 15380894
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg plain release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Study: 15380894
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg slow release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Study: 8062609
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/day) for 48 months in normotensive patients (NE group)
Study: 8062609
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/day) for 48 months in well-controlled hypertensive patients (HE group)
Study: 8062609
Drug: No enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: No enalapril treatment in normotensive patients (NC group)
Study: 8062609
Drug: No enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: No enalapril treatment in well-controlled hypertensive patients (HC group)
Study: 797515
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of nickel (double-blind test)
Study: 31175814
Drug: Passive Music
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Music Therapy (MT)
Study: 21289017
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium infusion (20‐mmol (5 g) magnesium sulfate for 5 consecutive days)
Study: 17202010
Drug: Dextromethorphan 30
Normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 30 mg (n = 25)
Study: 11524307
Drug: Acamprosate (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (two 333 mg tablets given three times daily for 180 days)
Study: 9773133
Drug: Triple epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple epidural mixture with adrenaline (bupivacaine 1 mg/ml, fentanyl 2 micrograms/ml, adrenaline 2 micrograms/ml)
Study: 9773133
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion without adrenaline
Study: 7824963
Drug: Native heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native heparin
Study: 1015603
Drug: Pethidine 150
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 150 mg intramuscularly
Study: 21746944
Drug: Posaconazole 100
Normalized name: posaconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 100 mg QD for 24 weeks
Study: 21746944
Drug: Posaconazole 200
Normalized name: posaconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 200 mg QD for 24 weeks
Study: 21746944
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg QD for 24 weeks
Study: 21746944
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg QD for 12 weeks
Study: 19505307
Drug: Non-hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormone therapy (non-HT)
Study: 9388905
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vaccine (5 mg rBS and 10^8 WC)
Study: 9388905
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vaccine (1 mg rBS and 10^8 WC)
Study: 1414052
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG solution (Oralav)
Study: 1414052
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (control group)
Study: 2578107
Drug: Verapamil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (150 micrograms/kg intravenous bolus followed by 150 micrograms/kg/hr intravenous infusion)
Study: 31649376
Drug: Daily mud
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mud packs and bicarbonate-alkaline mineral water baths
Study: 31649376
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mud packs and thermal hydrotherapy
Study: 31649376
Drug: Usual medication
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medication only
Study: 30155979
Drug: Ocrelizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocrelizumab (600 mg)
Study: 27325147
Drug: CT-based treatment
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Study: 27325147
Drug: AVS-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVS-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Study: 27325147
Drug: CT-based treatment
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-based treatment
Study: 27325147
Drug: AVS-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVS-based treatment
Study: 22056854
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 every 21 days for four cycles
Study: 22056854
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 35 mg/m2 + Cyclophosphamide + Trastuzumab 2 mg/kg weekly for 12 weeks
Study: 17258146
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day) + resistance exercise
Study: 12042982
Drug: Doxorubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (70 mg/m²) plus Ifosfamide (5 g/m²) followed by radiotherapy (chemotherapy arm)
Study: 12042982
Drug: Etoposide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) within 12 weeks (chemotherapy arm)
Study: 12042982
Drug: Etoposide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) combined with regional hyperthermia (RHT + chemotherapy arm)
Study: 12042982
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone with no further treatment (observation arm)
Study: 7814832
Drug: Oral GHBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GHBA administration
Study: 7814832
Drug: Oral GHBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GHBA and i.v. flumazenil administration
Study: 7814832
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and i.v. saline administration
Study: 2761740
Drug: Defibrotide alone
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide alone or in addition to conventional therapies
Study: 2761740
Drug: Defibrotide with
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide with conventional therapies
Study: 25739031
Drug: Ethinyl-estradiol 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl-estradiol 0.03 mg + Drospirenone 3 mg (EE + DRSP)
Study: 25739031
Drug: Ethinyl-estradiol 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl-estradiol 0.03 mg + Chlormadinone acetate 2 mg (EE + CMA)
Study: 23609610
Drug: 5‐HTP (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HTP (three 50‐mg capsules)
Study: 19952467
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day)
Study: 19952467
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (aspirin 100 mg and clopidogrel 75 mg per day)
Study: 10676676
Drug: Garlic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic treatment (300 mg three times a day for three months)
Study: 10676676
Drug: Garlic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic treatment or Placebo in LDL pattern A subjects
Study: 9377680
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy to maximal dose 6000 cGy (group I)
Study: 26900092
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with 66 Gy in 24 fractions and daily low dose cisplatin
Study: 21915516
Drug: 1.23% acidulated
Normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% acidulated phosphate fluoride gel, pH 4.1
Study: 21915516
Drug: 3% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% potassium oxalate gel, pH 4.1 (Oxa-Gel®)
Study: 21915516
Drug: iron sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iron sulfate gel (10 mmol/L FeSO4), pH 4.1
Study: 19033181
Drug: Intensive recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive recommended treatment and lifestyle advice in cardiovascular prevention (observational design)
Study: 16556241
Drug: Probable Chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probable Chronic Migraine (PCM) and Probable Analgesic-Abuse Headache (PAAH)
Study: 6111672
Drug: Prostacyclin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin administration
Study: 28651589
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation (BA) delivered by trained mental health nurses, consisting of 8 weekly 30-minute sessions.
Study: 28651589
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) in primary care.
Study: 21646576
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus group cognitive behavioral therapy (16 sessions of 2 hours each)
Study: 15528912
Drug: Toothpaste fluoridation
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste fluoridation (SnF2/Olaflur; 0.14% F‐) for 3 x 5 min daily
Study: 15528912
Drug: Intensive fluoridation
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive fluoridation (Toothpaste + Mouthrinse (SnF2/Olaflur; 0.025% F‐) for 3 x 5 min daily + Gel (NaF/Olaflur, 1.25% F‐) on days 1 and 3)
Study: 12019102
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% acyclovir-1% hydrocortisone cream (ME-609)
Study: 7494183
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium controlled-release matrix tablets (various formulations)
Study: 7494183
Drug: Stability testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stability testing of diclofenac sodium formulations
Study: 7494183
Drug: In-vivo study
Normalized name: Vivotif
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-vivo study of sustained release formulations
Study: 31157964
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (nonsteroidal antiandrogen therapy)
Study: 22392179
Drug: Zinc (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (10 mg for 2‐ to 11‐month‐olds and 20 mg for older children)
Study: 11916282
Drug: Methimazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (30 mg initial dose for at least 2 months, stopped 6 days before treatment)
Study: 11916282
Drug: Beta-blocker (atenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (atenolol 50-100 mg/d)
Study: 8522632
Drug: Phenytoin 200
Normalized name: phenytoin 200 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 200 mg and 300 mg once daily for 14 weeks
Study: 2401129
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release formulation
Study: 447112
Drug: Rowachol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowachol (2 capsules, three times a day for 48 hours)
Study: 447112
Drug: Rowachol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowachol (1 capsule, three times a day for 48 hours)
Study: 447112
Drug: Rowachol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowachol (4 capsules, four times a day for 48 hours)
Study: 24256450
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + placebo diclofenac
Study: 24256450
Drug: Diclofenac +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac + placebo paracetamol
Study: 24256450
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + diclofenac
Study: 21323785
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% hydrogen peroxide and sodium hypochlorite with composite resin
Study: 19674165
Drug: Dutasteride once
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride once daily for 52 weeks
Study: 16930852
Drug: D,L‐fenfluramine (FEN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L‐fenfluramine (FEN) 60 mg oral after a 7‐day cocaine‐free period
Study: 16930852
Drug: Cocaine (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (96 mg intranasal)
Study: 16930852
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mg cocaine)
Study: 20064249
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (vehicle)
Study: 15577414
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine gel with neurotoxin exposure
Study: 15577414
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine gel without neurotoxin exposure
Study: 11369252
Drug: Cisplatin-based front-line
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based front-line intraperitoneal therapy
Study: 11369252
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (not specified)
Study: 9534319
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin 12,500 IU twice daily for 3 months
Study: 9534319
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin treatment
Study: 3122278
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 mcg daily (given as two or four divided doses)
Study: 3122278
Drug: Cimetidine (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (conventional doses)
Study: 19501212
Drug: EE/CMA (ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CMA (ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg)